Navigation Links
BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
Date:9/25/2007

BRISBANE, Calif., Sept. 25 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that it has hired industry veterans Eric D. Malek as vice president of corporate development and Deborah A. Thomas as vice president for regulatory affairs.

"Over the last 12 years, Eric has played an integral role in clinical stage product partnerships involving major pharmaceutical and biotech companies and leading academic cancer centers and Debbie has been involved in the development of Avastin and Omnitarg, among other key oncology products, at Genentech," said G. Kirk Raab, acting chief executive officer and chairman of BiPar. "Their strong track records of success and experience will help as we begin Phase 2 testing of our promising lead compound, BSI-201, in three major cancers later this year and bring two more oncology compounds into the clinic next year."

BiPar is developing multiple compounds designed to inhibit PARP-1 (poly-ADP-ribose polymerase), an enzyme crucial to cell repair and upregulated in certain tumors.

Mr. Malek joins BiPar after seven years at Allos Therapeutics where, as vice president of corporate development, he played a pivotal role in shifting Allos' strategy to focus solely on oncology assets. He led the licensing effort to acquire both oncology products currently in their portfolio: pralatrexate, a novel antifolate currently in a registration trial in peripheral T-cell lymphoma, and RH1, currently in a Phase 1 trial for solid tumors. Before Allos, Mr. Malek held business development positions at Gilead Sciences, Inc., NeXstar Pharmaceuticals, Ilex Oncology, Inc. and Research Corporation Technologies. He has an undergraduate degree in biochemistry from the University of Arizona and an M.B.A. from the University of Michigan Business School.

Dr. Thomas worked at Genentech, Inc. for almost 17 years, most recently as a senior director of clinical regulatory affairs, where she oversaw products moving from late-stage research and development into Phase 1 clinical testing. Before that, she served as a team leader for Avastin, Omnitarg and Rapitva in the product portfolio management department. Prior to joining Genentech, Dr. Thomas began her career in the pharmaceutical industry as a toxicologist at Syntex Research. Dr. Thomas received her Ph.D. in toxicology and her B.S. in microbiology from the University of Kentucky.

About BiPar Sciences

BiPar Sciences Inc. (http://www.biparsciences.com) is a clinical-stage biopharmaceutical company developing and commercializing a novel class of tumor-selective drugs designed to meet the significant unmet needs of cancer patients. The Company's lead product candidate is BSI-201, which is now in early-stage clinical testing for advanced malignancies. The Company will be evaluating the potential of BSI-201 in multiple cancers and expects to file investigational new drug applications on as many as two additional cancer drug candidates in early 2008.


'/>"/>
SOURCE BiPar Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Choosing Lab Quality Management Software
3. Optimizing Quality Control Data Management
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
6. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
7. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
8. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
9. Monitoring Patient Glucose Levels: New Advances in software make it easier
10. New Advances in Gastric Diagnostics: Smaller is Better
11. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... clinical attributes? How are they positioned in the Global Dry eye market? ...
(Date:2/24/2017)... Juan Monteverde , founder and managing ... boutique securities firm headquartered at the Empire State Building ... that a class action lawsuit has been filed in the ... Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") on ... 2015 and December 30, 2016, inclusive (the "Class Period").  ...
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une ... d,annoncer les excellents résultats semestriels clos le 31 décembre ... présentation complète « Résultats et mise à jour sur la ... Faits marquants ... $ ; en hausse de 104 %) Bénéfice ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... With ... is so critically important that we all are aware of our options and ... is proud to announce the launch of its newest edition of "Vision and ...
(Date:2/24/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... Yisrayl makes an astounding statement when he says that the entire Bible was written ... the current times so plainly that anyone should be able to see the time ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations ... International Elite division on February 12th. Ms. Esparza qualified into this prestigious ... qualifier competition held in Las Vegas, Nevada. Frida is one of approximately 25 ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Club in Miami Beach to host its Swirl: Miami Wine Tasting Event on ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
Breaking Medicine News(10 mins):